Discover a new way to find and share stories you'll love… Learn about Reading Desk

Post Profile

No difference in death rates among patients exposed to common rheumatoid arthritis drugs

onfirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
read more


Copyright © 2011 Regator, LLC